Annual report pursuant to Section 13 and 15(d)

Revenue Recognition - Disaggregation of Revenue (Details)

v3.19.3.a.u2
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Disaggregation of Revenue [Line Items]      
Total revenues $ 68,458 $ 60,594 $ 50,024
Americas      
Disaggregation of Revenue [Line Items]      
Total revenues 13,039 15,370 15,575
EMEA      
Disaggregation of Revenue [Line Items]      
Total revenues 37,133 22,361 19,610
APAC      
Disaggregation of Revenue [Line Items]      
Total revenues 18,286 22,863 14,839
Product Sales      
Disaggregation of Revenue [Line Items]      
Total revenues 29,465 25,590 26,685
Research and Development Revenues      
Disaggregation of Revenue [Line Items]      
Total revenues 38,993 35,004 23,339
Performance Enzymes      
Disaggregation of Revenue [Line Items]      
Total revenues 58,156 47,073 42,333
Performance Enzymes | Americas      
Disaggregation of Revenue [Line Items]      
Total revenues 13,039 15,332 15,575
Performance Enzymes | EMEA      
Disaggregation of Revenue [Line Items]      
Total revenues 26,831 8,878 11,919
Performance Enzymes | APAC      
Disaggregation of Revenue [Line Items]      
Total revenues 18,286 22,863 14,839
Novel Biotherapeutics      
Disaggregation of Revenue [Line Items]      
Total revenues 10,302 13,521 7,691
Novel Biotherapeutics | Americas      
Disaggregation of Revenue [Line Items]      
Total revenues 0 38 0
Novel Biotherapeutics | EMEA      
Disaggregation of Revenue [Line Items]      
Total revenues 10,302 13,483 7,691
Novel Biotherapeutics | APAC      
Disaggregation of Revenue [Line Items]      
Total revenues $ 0 $ 0 $ 0